

**Shield Therapeutics plc**  
("Shield" or the "Company" or the "Group")

**Results of 2025 Annual General Meeting**

**London, UK, 22 May, 2025:** Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency with or without anemia ("ID/IDA") announces the voting results for each resolution set out in the Notice of Annual General Meeting 2025. The Board reports that all resolutions were passed: 1 to 10 passed as ordinary resolutions and 11 to 12 passed as special resolutions.

The following table shows the votes cast on each resolution:

	<b>VOTES FOR</b>	<b>%</b>	<b>VOTES AGAINST</b>	<b>%</b>	<b>WITHHELD VOTES</b>
Resolution 1	668,835,432	99.98%	133,164	0.02%	357,039
Resolution 2	668,122,080	99.89%	757,837	0.11%	445,718
Resolution 3	668,296,332	99.91%	583,585	0.09%	445,718
Resolution 4	668,137,993	99.89%	741,976	0.11%	445,666
Resolution 5	668,388,581	99.93%	491,388	0.07%	445,666
Resolution 6	668,133,181	99.89%	741,976	0.11%	450,478
Resolution 7	667,890,103	99.85%	1,027,158	0.15%	408,374
Resolution 8	668,672,292	99.96%	291,492	0.04%	361,851
Resolution 9	666,908,073	99.69%	2,080,523	0.31%	337,039
Resolution 10	666,442,645	99.60%	2,643,451	0.40%	239,539
Resolution 11	666,424,128	99.88%	808,577	0.12%	2,092,930
Resolution 12	666,417,127	99.88%	793,851	0.12%	2,114,657

**Notes:**

1. Number of shares in issue 1,041,690,484.
2. Details of the votes received on the resolutions are available on the Company's website:  
<https://www.shieldtherapeutics.com/corporate-documents/>.
3. Shield Therapeutics plc LEI: 213800G74QWY15FC3W71.

**For further information please contact:**

**Shield Therapeutics plc**  
Anders Lundstrom, CEO

[www.shieldtherapeutics.com](http://www.shieldtherapeutics.com)  
+44 (0) 191 511 8500

Santosh Shanbhag, CFO  
Stephanie Hicks, Investor Relations

[Investorrelations@shieldtx.com](mailto:Investorrelations@shieldtx.com)

**Nominated Adviser and Joint Broker**  
**Peel Hunt LLP**  
James Steel

+44 (0)20 7418 8900

**Joint Broker**  
**Cavendish Ltd**  
Geoff Nash / Rory Sale / Nigel Birks / Harriet Ward

+44 (0)20 7220 0500

**About Iron Deficiency and ACCRUFeR®/FeRACCRU®**

Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet medical need for both physicians and patients.

**ACCRUFeR®/FeRACCRU® (ferric maltol)** is a novel, stable, non-salt-based oral therapy for adults with ID/IDA. The drug has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR®/FeRACCRU®, including the product label, can be found at: [www.accrufer.com](http://www.accrufer.com) and [www.feraccru.com](http://www.feraccru.com).

**About Shield Therapeutics plc**

Shield is a commercial stage specialty pharmaceutical company that delivers ACCRUFer®/FeRACCRU® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has commercially launched its lead product ACCRUFer® in the U.S. through an exclusive, multi-year collaboration with a commercial partner. Internationally, it has secured licensing agreements with four specialty pharmaceutical companies, enabling commercialisation across key markets. The product is currently marketed in the UK, European Union, Australia, and New Zealand as FeRACCRU®, with additional exclusive partnerships in place for China and surrounding regions, South Korea, and as ACCRUFer® in Canada.

ACCRUFer®/FeRACCRU® has patent coverage until the mid-2030s.

ACCRUFer®/FeRACCRU® are registered trademarks of Shield Therapeutics.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGPKBBKABKDPPB